Medirama and A-Face Sign MOU for New Drug Development

Medirama announced on the 29th that it signed a Memorandum of Understanding (MOU) with Apace on the 25th to develop a new drug pipeline.

Moon Hanlim, CEO of Medirama (left), and Jang Injin, CEO of A-Face, are posing for a commemorative photo at the business agreement signing ceremony.
[Photo by Medirama]

Based on their expertise and accumulated experience, the two companies agreed to enhance and expand their analytical capabilities to provide new clinical research strategy solutions, mutually promoting cooperation and establishing a collaborative work system.

Medirama is a clinical development specialist company established in 2021. It possesses a one-stop clinical platform called 'ABCD' and is recognized for its expertise in anticancer drug development. ABCD stands for 'Advanced Business Model for Clinical Development.' It is a platform that aims to operate high-quality clinical trials at high speed by addressing clinical development strategies, clinical trial operations, and problems and questions arising during clinical development.

Apace originated from the Department of Clinical Pharmacology at Seoul National University College of Medicine and was established in 2018 as a Good Clinical Laboratory Practice (GCLP) certified institution. It conducts pharmacokinetic marker analysis, pharmacokinetics/pharmacodynamics, and statistical analysis. Through more than 30 clinical trial consultations and strategy developments annually with domestic and international pharmaceutical companies and bio ventures, it provides end-to-end new drug development solutions, including early clinical trials.

Moon Hanlim, CEO of Medirama, said, "Anticancer drug development is highly competitive, complex, and requires meticulous strategies," adding, "The collaboration between the two companies is expected to provide profound assistance to many companies."

Jang Injin, CEO of Apace, also said, "We are pleased to sign an agreement with Medirama, which possesses expertise in the field of anticancer new drug development," and added, "Through high-level clinical pharmacological analysis and consultation, we expect to create a synergy effect for establishing efficient new drug clinical development strategies."

This content was produced with the assistance of AI translation services.